Invo Fertility (IVF)Director sold ~$6

~$6

Approx. value · 4 sh @ $1.52

3

Holds after · shares reported

Traded

Dec 3, 2025

Filed

Dec 6, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 6, 2025Company filing · Form 8-K · Unregistered sharesSold new shares without registering them
2. Oct 16, 2025Company filing · Form 8-K · Unregistered sharesSold new shares without registering them
3. Nov 17, 2025Company filing · Form 8-K · ResultsReported its results
4. Nov 26, 2025Company filing · Form 8-K · Bylaws or charter, Other newsChanged its bylaws, charter or fiscal year, and reported other company news
5. Dec 2, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
6. Dec 3, 2025 · this disclosureInsiderDirector sold ~$6 of IVF shares in the open market

What came next

1. Dec 15, 2025Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
2. Dec 30, 2025Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“Effective December 30, 2025, the board of directors (the “Board”) of INVO Fertility, Inc. (the “Company”) appointed Terah Krigsvold as the Company’s chief financial officer.”
3. Jan 22, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
4. Jan 28, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
5. Feb 18, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 3 more items)“On February 18, 2026, the Company, through Buyer, consummated its acquisition (the “Acquisition”) of Family Beginnings P.C. (the “Clinic”) for a combined purchase price of $760,000, of which $360,000 was paid in cash on the closing date (a net amount of $210,000 after a $150,000 holdback) and $400,000 was paid on the closing date in 400 shares of the Company’s Series D Preferred (as defined under Item 5.03 below).”
6. Mar 25, 2026Company filing · Form 8-K · Bylaws or charter, Other newsChanged its bylaws, charter or fiscal year, and reported other company news

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Invo Fertility

For Invo Fertility, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IVF page.

Other recent filings by Matthew K Szot, Director

• SEC Form 4 at Cadrenal Therapeutics (CVKD)Dec 31, 2025
• SEC Form 4 at Senestech (SNES)Nov 17, 2025
• SEC Form 4 at Cadrenal Therapeutics (CVKD)Oct 28, 2025
• SEC Form 4 at Cadrenal Therapeutics (CVKD)Oct 28, 2025
• SEC Form 4 at Cadrenal Therapeutics (CVKD)Oct 14, 2025

The full history of Matthew K Szot, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Invo Fertility

• SEC Schedule 13GOct 9, 2026

Everything OQRO holds on this company is on its IVF page.